PinnyPeptide

TB-500 Fragment 17-23 vs VIP (Vasoactive Intestinal Peptide)

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

TB-500 Fragment 17-23

Healing & Recovery

The 7-amino-acid active fragment of TB-500, isolated for cell-migration effects.

Peptide B

VIP (Vasoactive Intestinal Peptide)

Healing & Recovery

Broad neuropeptide with anti-inflammatory, immunomodulatory, and vasodilatory activity.

Typical vial

10 mg

Typical dose

2000-5000 mcg

Half-life

Estimated minutes to a few hours (much shorter than full TB-500 due to lack of N/C-terminal protection)

FDA status

Not FDA approved for any human or veterinary use. No clinica…

Typical vial

5 mg

Typical dose

50-200 (intranasal) mcg

Half-life

~2 minutes (plasma); longer functional duration via tissue distribution

FDA status

Not FDA approved as therapeutic. VIP analog aviptadil receiv…

TB-500 Fragment 17-23 effects

  • Binds G-actin and modulates actin polymerization
  • In vitro promotion of keratinocyte and endothelial cell migration
  • Pro-angiogenic activity in cell-based assays
  • Pro-healing effects on cultured fibroblasts
  • Anti-inflammatory effects (limited to in vitro evidence)
  • Potentially shared but reduced systemic activity vs full TB-500

VIP (Vasoactive Intestinal Peptide) effects

  • Vasodilation and smooth-muscle relaxation
  • Broad anti-inflammatory effects via VPAC1/VPAC2
  • Immunomodulatory: shifts T-helper balance toward Th2/regulatory
  • Circadian rhythm organization (suprachiasmatic nucleus activity)
  • Lung-protective effects in ARDS and pulmonary hypertension models
  • Used clinically in CIRS / biotoxin-illness recovery protocols

TB-500 Fragment 17-23 side effects

  • Injection site irritation or redness
  • Lethargy (anecdotal, mechanism unclear)
  • Mild flu-like symptoms at higher doses (rare)
  • Headache
  • Unknown long-term effects — no human safety data

VIP (Vasoactive Intestinal Peptide) side effects

  • Hypotension and flushing (especially with rapid IV)
  • Tachycardia
  • Headache
  • GI effects (cramping, diarrhea at high doses)
  • Intranasal: occasional nasal irritation

TB-500 Fragment 17-23 dosing ranges

Injury recovery (extrapolated)

2-5 mg · Twice weekly SubQ · 4-6 weeks

Tendon/ligament support (extrapolated)

2-5 mg · Twice weekly SubQ · 4-8 weeks

Loading phase (anecdotal)

5 mg · Twice weekly for 2-3 weeks · Then maintenance

VIP (Vasoactive Intestinal Peptide) dosing ranges

Intranasal CIRS protocol (off-label)

50 mcg · 4 sprays daily · Per Shoemaker protocol; months to years for full restoration

Research / immunomodulation

Variable per protocol · Per protocol · Per protocol

Full TB-500 Fragment 17-23 guide → Full VIP (Vasoactive Intestinal Peptide) guide →

TB-500 Fragment 17-23 vs VIP (Vasoactive Intestinal Peptide) — common questions

What is the difference between TB-500 Fragment 17-23 and VIP (Vasoactive Intestinal Peptide)?

TB-500 Fragment 17-23: The 7-amino-acid active fragment of TB-500, isolated for cell-migration effects. Typical dose 2000-5000 mcg. VIP (Vasoactive Intestinal Peptide): Broad neuropeptide with anti-inflammatory, immunomodulatory, and vasodilatory activity. Typical dose 50-200 (intranasal) mcg. Both fall under the Healing & Recovery category.

Can you stack TB-500 Fragment 17-23 and VIP (Vasoactive Intestinal Peptide)?

Stacking TB-500 Fragment 17-23 with VIP (Vasoactive Intestinal Peptide) is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, TB-500 Fragment 17-23 or VIP (Vasoactive Intestinal Peptide)?

TB-500 Fragment 17-23 is typically dosed: Twice weekly SubQ for Injury recovery (extrapolated); Twice weekly SubQ for Tendon/ligament support (extrapolated); Twice weekly for 2-3 weeks for Loading phase (anecdotal). VIP (Vasoactive Intestinal Peptide) is typically dosed: 4 sprays daily for Intranasal CIRS protocol (off-label); Per protocol for Research / immunomodulation.

Are TB-500 Fragment 17-23 and VIP (Vasoactive Intestinal Peptide) FDA approved?

TB-500 Fragment 17-23: Not FDA approved for any human or veterinary use. No clinical trials have been conducted on this specific fragment. VIP (Vasoactive Intestinal Peptide): Not FDA approved as therapeutic. VIP analog aviptadil received Emergency Use Authorization consideration for COVID-19 ARDS but not full approval.

Related peptide comparisons

ara-290 vs tb-500-frag-17-23bpc-157 vs tb-500-frag-17-23ghk-cu vs tb-500-frag-17-23kpv vs tb-500-frag-17-23ll-37 vs tb-500-frag-17-23ara-290 vs vip

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free